BridgeMD
An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms
EU CTIS ID: 2025-523699-21-00
What this study is testing
To assess safety of intravenous infusion of in vitro expanded adipose tissue-derived mesenchymal stromal cells (ASCs) used for allogenic treatment of children with autism spectrum disorder (ASD) and gastrointestinal symptoms.
- Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Aged 6-18 years (both inclusive)
- Diagnosis of autism spectrum disorder
- Ongoing gastrointestinal symptoms
You likely can't join if
- If known genetic syndrome or pathogenic mutation or copy number variation associated with autism spectrum disorder
- Known CNS-infection (now or previously) and/or HIV positivity
- Primary immunodeficiency disorder or autoimmune cytopenia
- Celiac disease or inflammatory bowel disease (Crohn’s disease or ulcerative colitis)
- Current treatment with cytotoxic drugs or systemic administered glucocorticoids and/or immunosuppressive therapy or other anti-inflammatory medication (except nonsteroidal anti-inflammatory drugs)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.